One more hope ...

[stepan13]

In patients with idiopathic Parkinson disease (PD), researchers assessed the safety and tolerability of multiple intravenous infusions of PRX002. This multicenter, randomized, double-blind, placebo-controlled, multiple ascending-dose trial included 80 participants aged 40-80 years with mild to moderate idiopathic PD (Hoehn and Yahr stages 1-3) who were randomized to six ascending-dose cohorts—PRX002 (0.3 mg/kg, 1.0 mg/kg, 3.0 mg/kg, 10 mg/kg, 30 mg/kg, or 60 mg/kg)—or placebo. The investigators found that single and multiple doses of PRX002 were generally safe and well tolerated, and led to robust binding of peripheral α-synuclein and dose-dependent increases of PRX002 in cerebrospinal fluid (CSF), reaching CSF levels that may be expected to engage extracellular aggregated α-synuclein in the brain.

[JANVAN]

Wow, thank you for sharing !!

Wonder if there will an extra effect combined with i.v. detox (with DMPS, DMSA, (Irminix), Glutathion,...) infusions.......

Perhaps in a cooperation between a MD and ND ??

[JANVAN]

And the link or just google PRX.....?

[stepan13 in reply to JANVAN]

I am sorry! mdlinx.com/journal-summarie...

[park_bear]

prothena.com/pipeline/prx002/

"Prasinezumab (PRX002/RG7935) is an investigational monoclonal antibody that targets α-synuclein, a protein that is believed to misfold and aggregate to form the protein structures that are highly implicated in Parkinson’s disease pathology."

Available to trial participants only. It will still be years until this is approved. If approved is likely to be quite expensive and may never be a generic.